Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 109 Records) |
| Query Trace: Lung Neoplasms and EML4[original query] |
|---|
| Early Blood-based Liquid Biopsy in Patients with Treatment-naïve Metastatic Adenocarcinoma of the Lung: A Case Series. The Israel Medical Association journal : IMAJ 2020 Dec 22 (12): 784-787. Peled Michael, Bar Jair, Avni Liat, Chatterji Sumit, Somech Dafna, Dvir Addie, Soussan-Gutman Lior, Onn Am |
| Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA. EBioMedicine 2020 Nov 62 103103. Dietz Steffen, Christopoulos Petros, Yuan Zhao, Angeles Arlou Kristina, Gu Lisa, Volckmar Anna-Lena, Ogrodnik Simon J, Janke Florian, Fratte Chiara Dalle, Zemojtel Tomasz, Schneider Marc A, Kazdal Daniel, Endris Volker, Meister Michael, Muley Thomas, Cecchin Erika, Reck Martin, Schlesner Matthias, Thomas Michael, Stenzinger Albrecht, Sültmann Holg |
| Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2020 10 149 154-161. Tao Hong, Shi Liang, Zhou Aoxue, Li Hongxia, Gai Fei, Huang Zhan, Che Nanying, Liu Z |
| High Tumor Mutation Burden and DNA Repair Gene Mutations are Associated with Primary Resistance to Crizotinib in ALK-Rearranged Lung Cancer. OncoTargets and therapy 2021 9 14 4809-4817. Xiao Dakai, Deng Qiuhua, He Dongyun, Huang Ying, Liang Wenchi, Wang Fengnan, Yang Haiho |
| Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance. Lung cancer (Amsterdam, Netherlands) 2021 8 160 32-35. Liu Di, Xu Xinyan, Wen Junmiao, Zhang Chi, Fan M |
| Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation. Case reports in oncology 2021 7 14 (2): 1085-1091. Nguyen Thai Hoa Thi, Pham Xuan Dung, Dao Khanh Linh, Vo Thanh To |
| Relationship between clinical features and gene mutations in non-small cell lung cancer with osteoblastic bone metastasis. Cancer treatment and research communications 2021 Jul 28 100440. Takahara Yutaka, Nakase Keisuke, Nojiri Masafumi, Kato Ryo, Shinomiya Shohei, Oikawa Taku, Mizuno Shi |
| Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. Lung cancer (Amsterdam, Netherlands) 2021 Jul 159 66-73. Mondaca Sebastian, Lebow Emily S, Namakydoust Azadeh, Razavi Pedram, Reis-Filho Jorge S, Shen Ronglai, Offin Michael, Tu Hai-Yan, Murciano-Goroff Yonina, Xu Chongrui, Makhnin Alex, Martinez Andres, Pavlakis Nick, Clarke Stephen, Itchins Malinda, Lee Adrian, Rimner Andreas, Gomez Daniel, Rocco Gaetano, Chaft Jamie E, Riely Gregory J, Rudin Charles M, Jones David R, Li Mark, Shaffer Tristan, Hosseini Seyed Ali, Bertucci Caterina, Lim Lee P, Drilon Alexander, Berger Michael F, Benayed Ryma, Arcila Maria E, Isbell James M, Li Bob |
| One-Step Polymerase Chain Reaction-Free Nanowire-Based Plasma Cell-Free DNA Assay to Detect EML4-ALK Fusion and to Monitor Resistance in Lung Cancer. The oncologist 2021 Jul . Lee Youngjoo, Cho Youngnam, Park Eun Young, Park Seong-Yun, Hwang Kum Hui, Han Ji-Yo |
| Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer. ESMO open 2021 6 6 (3): 100161. El Shafie R A, Seidensaal K, Bozorgmehr F, Kazdal D, Eichkorn T, Elshiaty M, Weber D, Allgäuer M, König L, Lang K, Forster T, Arians N, Rieken S, Heussel C-P, Herth F J, Thomas M, Stenzinger A, Debus J, Christopoulos |
| Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib. Translational lung cancer research 2021 4 10 (3): 1525-1535. Li Jingjing, Zhang Bin, Zhang Yu, Xu Feng, Zhang Zhenfa, Shao Lin, Yan Chunhe, Ulivi Paola, Denis Marc G, Christopoulos Petros, Thomas de Montpréville Vincent, Bernicker Eric H, van der Wekken Anthonie J, Wang Changli, Yue Dongshe |
| Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study. Lung cancer (Amsterdam, Netherlands) 2021 12 163 7-13. Tan D S-W, Thomas M, Kim D-W, Szpakowski S, Urban P, Mehra R, Chow L Q M, Sharma S, Solomon B J, Felip E, Camidge D R, Vansteenkiste J, Petruzzelli L, Pantano S, Shaw A |
| Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study. Genes, chromosomes & cancer 2021 10 61 (4): 177-186. Kang Jin, Deng Qiu-Mei, Peng Kai-Cheng, Li Peng, Zhu Bao-Ting, Wang Pan, Chu Xiang-Peng, Zhong Wen-Zhao, Chen Hua-Jun, Wang Wen-Xian, Chen Hua-Fei, Rao Chuang-Zhou, Xu Chun-Wei, Yang Jin- |
| Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency. Clinical lung cancer 2021 1 22 (4): e519-e527. Bustamante Alvarez Jean G, Janse Sarah, Owen Dwight H, Kiourtsis Stephanie, Bertino Erin M, He Kai, Carbone David P, Otterson Gregory |
| Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2022 9 17 (12): 1404-1414. Ou Sai-Hong Ignatius, Nishio Makoto, Ahn Myung-Ju, Mok Tony, Barlesi Fabrice, Zhou Caicun, Felip Enriqueta, de Marinis Filippo, Kim Sang-We, Pérol Maurice, Liu Geoffrey, Migliorino Maria Rita, Kim Dong-Wan, Novello Silvia, Bearz Alessandra, Garrido Pilar, Mazieres Julien, Morabito Alessandro, Lin Huamao M, Yang Hui, Niu Huifeng, Zhang Pingkuan, Kim Edward |
| Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. JAMA network open 2022 Jun 5 (6): e2215589. Liu Yufei, Zhang Zhe, Rinsurongkawong Waree, Gay Carl M, Le Xiuning, Ning Matthew S, Lewis Jeff, Rinsurongkawong Vadeerat, Lee J Jack, Roth Jack, Swisher Stephen, Gandhi Saumil, Lee Percy P, Gibbons Don L, Vaporciyan Ara A, Heymach John V, Zhang Jianjun, Lin Steven |
| Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial. Lung cancer (Amsterdam, Netherlands) 2022 Jul 169 67-76. Soo Ross A, Huat Tan Eng, Hayashi Hidetoshi, Seto Takashi, Lin Chia-Chi, Ou Sai-Hong Ignatius, Kim Dong-Wan, Liu Geoffrey, Abbattista Antonello, Martini Jean-François, Hooi Wong Chew, Toffalorio Francesca, Solomon Benjamin |
| Characteristics of Genomic Alterations in Pericardial Effusion of Advanced Non-small Cell Lung Cancer. Frontiers in genetics 2022 6 13 850290. He Jiaxue, Hu Xintong, Chen Liguo, Liu Qiaoliang, Jiang Yanfa |
| Special issue "The advance of solid tumor research in China": Real-world clinical outcomes of alectinib for advanced nonsmall-cell lung cancer patients with ALK fusion in China. International journal of cancer 2022 5 152 (1): 15-23. Su Chunxia, Zhou Juan, Qiang Huiping, Zhao Jing, Chang Qing, Ji Xianxiu, Li Jiaqi, Xie Mengqing, Chu Tianqi |
| Use of Low-Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non-Small-Cell Lung Cancer: A Multicenter Case Series. JCO precision oncology 2022 2 2 1-10. Jacobs Miriam T, Mohindra Nisha A, Shantzer Lindsey, Chen Ingrid L, Phull Hardeep, Mitchell William, Raymond Victoria M, Banks Kimberly C, Nagy Rebecca J, Lanman Richard B, Christensen James, Patel Jyoti D, Clarke Jeffrey, Patel Sandip |
| Screening of significant oncogenic changes in air pollution-related lung cancer in Chinese population. Translational cancer research 2022 2 9 (7): 4341-4353. Kanwal Madiha, Ding Xiaojie, Lin Weiming, Cao |
| Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib. Translational cancer research 2022 2 8 (4): 1630-1634. Zhu You-Cai, Wan Bing, Wu Li-Xin, Li Xing-Liang, Wang Wen-Xian, Xu Chun-Wei, Zhuang Wu, Wei Jian-Guo, Du Kai- |
| Analysis of real-word mutations of lung cancer driver genes in five regions of China. Translational cancer research 2022 2 8 (7): 2581-2592. Sun Mengyao, Guo Ye, Shao Guoguang, Duan Xiumei, Yang Zhiguang, Zhang Peng, Liu Yunpeng, Dong Yutong, Wang Xu, Xu Yinghui, Sun Chao, Ma Kew |
| Molecular determinants of clinical outcomes for anaplastic lymphoma kinase-positive non-small cell lung cancer in Chinese patients: A retrospective study. Cancer genetics 2022 12 270-271 32-38. Guan Maojing, Xu Jianping, Shi Qingmi |
| Comprehensive Comparative Molecular Characterization of Young and Old Lung Cancer Patients. Frontiers in oncology 2022 1 11 806845. Hu Mingming, Tan Jinjing, Liu Zhentian, Li Lifeng, Zhang Hongmei, Zhao Dan, Li Baolan, Gao Xuan, Che Nanying, Zhang Tongm |
| Real-world challenges in undertaking NTRK fusion testing in non-small cell lung cancer. Journal of thoracic disease 2023 8 15 (7): 3811-3817. Ashleigh Poh, Abdelaziz Sammour, Jared Mathai, Joanne Peverall, Chris Van Vliet, Khashayar Asadi, Sagun Para |
| Next Generation Sequencing Analysis and its Benefit for Targeted Therapy of Lung Adenocarcinoma. Cancer genomics & proteomics 2023 7 20 (4): 404-411. Vlastimil Kulda, Jiri Polivka, Martin Svaton, Tomas Vanecek, Marcela Buresova, Katerina Houfkova, Mahyar Sharif Bagheri, Tereza Knizkova, Bohuslava Vankova, Jindra Windrichova, Petr Macan, Vaclav Babuska, Martin Pes |
| Lung cancer presenting with central nervous system metastasis: Clinicopathological and molecular analysis of 171 cases. Annals of diagnostic pathology 2023 1 63 152082. Demleitner Madeleine, Erlenbach-Wünsch Katharina, Coras Roland, Erber Ramona, Polifka Iris, Eyüpo?lu Ilker, Fuchs Florian, Hartmann Arndt, Agaimy Abb |
| Impact of EML4-ALK variants and co-occurring TP53 mutations on duration of first-line ALK tyrosine kinase inhibitor treatment and overall survival in ALK fusion-positive NSCLC: Real-world outcomes from the GuardantINFORM database. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2024 7 . Kaushal Parikh, Anastasios Dimou, Konstantinos Leventakos, Aaron S Mansfield, Mohamed Shanshal, Yin Wan, Huamao M Lin, Sylvie Vincent, Jennifer Elliott, Ioana R Bon |
| Clinical difference on the variants and co-mutation in a Chinese cohort with ALK-positive advanced non-small cell lung cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2024 4 . Ying Fu, Qing Liu, Xiaohan Wang, Liangchao Sun, Xiao Han, Xue Me |
- Page last reviewed:Feb 1, 2024
- Content source: